Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15366422 | 0.76 | NOS1 (0.51) | NOS1ELANE | |
| SCHEMBL14940665 | 0.76 | NOS1 (0.51) | NOS1ELANE | |
| SCHEMBL11234194 | 0.74 | NOS1 (0.41) | NOS1ELANE | |
| SCHEMBL11234179 | 0.74 | NOS1 (0.41) | NOS1ELANE | |
| SCHEMBL8195539 | 0.73 | ELANE (0.34) | NOS1ELANE | |
| SCHEMBL11237686 | 0.72 | NOS1 (0.41) | NOS1ELANE | |
| SCHEMBL11227115 | 0.72 | NOS1 (0.34) | NOS1ELANE | |
| SCHEMBL2551318 | 0.70 | ELANE (0.44) | NOS1ELANE | |
| SCHEMBL14936429 | 0.69 | ELANE (0.38) | NOS1ELANE | |
| SCHEMBL11224763 | 0.68 | NOS1 (0.31) | NOS1ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120041038-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120041039-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-20110237579-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041039-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, AADAT | NOS1 819/4885ELANE 2372/4885 |
| US-20120041038-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, AADAT | NOS1 819/4885ELANE 2372/4885 |
| US-20110237579-A1 | INHIBITORS OF HCV NS5A | MAVS, HAVCR2, EIF2AK2 | NOS1 3139/4885ELANE 4051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.